Affimed (AFMD) Reports Q4 Loss of EUR0.60/sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Affimed Reports 2022 Financial Results and Operational Progress
March 23, 2023 6:30 AM EDTAFM13 combination with AB-101 NK cells: On track for IND filing in H1 2023 and initiation of clinical study in 2023AFM13 monotherapy REDIRECT data: Oral presentation at the AACR annual meetingAFM24: Data from the three ongoing studies expected to be presented at scientific conferences in Q2 or Q3 of 2023AFM28: Clinical phase 1 study is open and recruiting; clinical trial applications now approved in four European countries including Belgium, France, Denmark and SpainAnticipated cash runway into 2025: As of December 31,... More
